





The definition of a signal as provided by the CIOMS Working Group 8 is:

"... information that arises from one or multiple sources (including observations and experiments), which suggests a new potentially causal association, or a new aspect of a known association, between an intervention and an event or set of related events, either adverse or beneficial, that is judged to be of sufficient likelihood to justify verificatory action"

Simply put: A signal is a hypothesis suggesting a causal relationship exists between an AE and the medication



NEW – Unexpected/Unlisted

OLD – Changes in frequency or severity

IMPORTANT MODULES

- GVP Module IX - Signal Management (https://pharmacovigilancemadeeasy.com/gv p-module-ix)

- GVP Module XV - Safety Communication (https://pharmacovigilancemadeeasy.com/gv p-module-xv)



The process of signal management in pharmacovigilance is a set of activities which aim to determine

This is the process by which the suspected causal association between AE and a drug is validated/confirmed leading to recommended action regulatory action to all stakeholders

The process for managing signals within pharmaceutical companies and regulatory

• whether there are new risks associated with a particular drug, or • whether risks associated with a particular drug have changed



authorities/pharmacovigilance centers must systematically address the following steps:

- Signal detection
- Validation and Confirmation
- Analysis
- Prioritization
- Assessment
- Recommending action

At the GST you seek endorsement for: Valid/Refuted, Risk prioritization (severe, moderate or mild - determines the recommended actions and timelines), risk categorization (important identified, important potential)



TYPES

- (ROR, EBOS)
- The act of looking for and/or identifying signals using the event data from any
 - source

- Qualitative: Clinical Judgement
 - (Inadequate/Limited information,
 - Adequate but with confounders, signal index case)
- Quantitative: Disproportional statistics



from:

- spontaneous reporting
- active monitoring systems
- interventional studies (clinical trials)
- non-clinical studies (e.g. animal toxicology studies)
- meta-analyses (i.e. mathematical pooling of all the clinical trial data)
- other relevant sources.

Sources for the detection of signals can come

- non-interventional studies
 - (pharmacoepidemiology studies)

- systemic reviews (i.e. thorough review of
 - the published literature)